GB-0669 (anti-SARS-CoV-2 antibody)

Summary

GB-0669 is an anti-SARS-CoV-2 antibody from Generate:Biomedicines. The source describes it as monoclonal antibody. It is being developed for COVID-19 (prevention/treatment). ClinicalTrials.gov lists it at Phase 1 (completed) under NCT07050511. The AI role named in the source is molecule design. Registry records: NCT07050511, Phase 1, completed, updated Jul 3, 2025. About the company, based in United States: Flagship-founded generative biology platform that designs protein therapeutics computationally; lead asset GB-0895 (anti-TSLP, golukibart) is in Phase 3 for severe asthma. Phase 1 completed. Generate says internal development is deprioritized. The latest dated source is from Jul 3, 2025.

Built only from the sources listed on this page.

Facts

Company

Generate:Biomedicines

Indication

COVID-19 (prevention/treatment)

Therapeutic area

Infectious disease

Modality

Monoclonal antibody

AI role

Molecule design

Phase in the source

Phase 1 (completed; internal development deprioritized), as of Jul 3, 2025

Phase source

Registry

Board column

Phase 1

AI evidence

AI source: Paper

“GB-0669 is a half-life-extended monoclonal antibody optimized using artificial intelligence.”

Source: paper (opens in new tab)

Trial records

• NCT07050511 on ClinicalTrials.gov (opens in new tab) Phase 1 Completed Updated Jul 3, 2025

Milestone timeline

1. Jul 3, 2025 Source

   ClinicalTrials.gov record: Phase 1 (completed; internal development deprioritized)

   Phase 1 completed. Generate says internal development is deprioritized.

   ClinicalTrials.gov record (opens in new tab)

2. Jul 3, 2025 Registry

   NCT07050511 record updated

   Phase 1, Completed

   NCT07050511 (opens in new tab)

About Generate:Biomedicines

Flagship-founded generative biology platform that designs protein therapeutics computationally; lead asset GB-0895 (anti-TSLP, golukibart) is in Phase 3 for severe asthma.

Source, Feb 26, 2026

Generate:Biomedicines company profile